VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
EVAX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
EVAXEvaxion Biotech A/S
$2.78$18M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
EVAX logo

Evaxion Biotech A/S

EVAX
NASDAQ · Drug Discovery Platforms
$2.78
At close - Nov 17, 4:00 PM EST - USD
Market Cap$18M
P/E-0.1x
52W High$6.92
Volume27K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2025Q4

Volatile Milestone Revenue Masks Persistent Operational Deficits

Evaxion Biotech remains a high-risk, clinical-stage entity whose valuation is tethered to the success of its AI-driven PIONEER platform rather than consistent commercial performance.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

EVAX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

No Data

No recent earnings data

02

Valuation risk

-100% Peers

P/E is 100% below peer median

03

Market leadership

RS 33 · Lag

Laggard (Underperforming 67% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystConfirmed earnings · Nov 19

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
EVAX-40.98%
S&P 500 (^GSPC)+7.21%
1-Year Return
EVAX-46.64%
S&P 500 (^GSPC)+10.03%
3-Year Return
EVAX-92.38%
S&P 500 (^GSPC)+64.27%
5-Year Return
EVAX-99.00%
S&P 500 (^GSPC)+61.13%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$8M+125.1% YoY
Net income FY25
-$8M+27.1% YoY
Free cash flow FY25
-$7M+48.6% YoY
Operating margin FY25
-122.7%+317.9 pts YoY
ROIC (FY25)-294.3%
Avg ROIC 5Y-513.5%
ROE (TTM)-61.4%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·5d ago
Evaxion announce 2027 financial calendar

COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces its financial calendar for 2027 as summarized below:

GlobeNewsWire·Nov 9, 2026
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement

COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.

GlobeNewsWire·Nov 6, 2026
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, November 6, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).

Defense World·Nov 6, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Evaxion A/S (NASDAQ:EVAX) Financial Analysis

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk. Valuation and Earnings This table compares Evaxion A/S

Filtered for Evaxion Biotech A/SMore Headlines
04

Compare before deciding

Benchmark EVAX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Evaxion Biotech A/S (EVAX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
EVAX logoEVAXEvaxion Biotech A/SCurrent
$2.78$17.56M-0.13125.12%-115.49%-61.39%—
NEON logoNEONNeonode Inc.
$0.56$9.42M1.16-33.66%397.84%34.15%—
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
NKTR logoNKTRNektar Therapeutics
$35.91$1.23B-6.92-43.89%-339.67%-29.31%—
IOVA logoIOVAIovance Biotherapeutics, Inc.
$7.53$3.36B-15.5760.6%-58.19%-29.71%—
GILD logoGILDGilead Sciences, Inc.
$170.26$211.39B-55.142.39%-12.47%-21.84%1.87%

Compare EVAX vs Peers

Evaxion Biotech A/S (EVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NEON

Most directly comparable listed peer for EVAX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare EVAX against a more recognizable public peer.

Peer Set

Compare Top 5

vs NEON, IMVT, NKTR, IOVA

Get notified when EVAX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

EVAX Frequently Asked Questions

Evaxion Biotech A/S (EVAX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Evaxion Biotech A/S's revenue?

Evaxion Biotech A/S (EVAX) reported $7.5M in revenue in fiscal year 2025, which is also its trailing twelve months.

How fast is Evaxion Biotech A/S growing?

Evaxion Biotech A/S (EVAX) grew revenue by 135.9% over the trailing twelve months, compared with the twelve months before.

Is EVAX profitable?

No. Evaxion Biotech A/S (EVAX) reported a net loss of $8.7M over the trailing twelve months.

Dividend & Returns
What is EVAX's return on equity?

Evaxion Biotech A/S (EVAX) had a return on equity (ROE) of -61.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What if you invested $1,000 in EVAX back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →